Altre lingue Marksans Pharma Limited

Azioni

MARKSANS

INE750C01026

Tempo differito NSE India S.E. Altri mercati azionari 08:11:37 14/05/2024			Variaz. 5gg	Var. 1 gen.
158,6 ^INR	+1,67%		+0,57%	-1,43%

14/02	Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024
13/02	Marksans Pharma Limited riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA	18/04
Marksans Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02
Marksans Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
Marksans Pharma Arm Gets UK Regulator's Approval to Market Cyanocobalamin Tablets	06/11
Marksans Pharma Undergoes Successful Inspection from German Health Authorities	01/11
CARE Affirms A+ Rating on Marksans Pharma's Long-term Bank Financing; Outlook Stable	12/10/23
Marksans Pharma Gets US FDA Nod for Esomeprazole Magnesium Delayed-Release Capsules	03/10/23
Marksans Pharma Limited Announces US FDA Approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg	03/10/23
Marksans Pharma Limited Approves Payment of Dividend	28/08/23
Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director	28/08/23
Marksans Pharma Gets US FDA's Final Approval for Generic Cough Medicine	22/08/23
Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets	22/08/23
Marksans Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/08/23
Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23	08/08/23
Marksans Pharma's Goa Plant Gets Two Observations from US FDA	07/08/23
Marksans Pharma Gets US FDA Nod for Pain Relief Drug	12/07/23
Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg	12/07/23
Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023	30/05/23
Marksans Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	30/05/23
Marksans Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Marksans Pharma Limited

Azioni

MARKSANS

INE750C01026

Altre lingue

Filtri